Skip to content

Study · Non-randomized trial · 1997

4 results

Growth hormone secretagogues in children with altered growth.

Bercu BB, Walker RF

Acta paediatrica (Oslo, Norway : 1992). Supplement1 Nov 1997Cited by 4 (Europe PMC)

PMID9401554 (opens in a new tab)DOI10.1111/j.1651-2227.1997.tb18385.x (opens in a new tab)PepBankPUB-09401554
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In children, the peak GH response to GHRP‑2 was lower in GH-deficient children (20.1 micrograms/l) than in controls (42.2 micrograms/l).

    In plain wordsIn children, the growth hormone peak after GHRP‑2 was lower in children with growth hormone deficiency than in control children.

    Peptide
    GHRP-2
    Outcome
    DecreasePeak GH response to GHRP-2, GH-deficient versus control children
    Study

    n: not reported in source

    Comparator
    Control children
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Peak GH response
    20.1 micrograms/l
    GH-deficient children
    Peak GH response
    42.2 micrograms/l
    control children

    Source sentences

    Summary
    The mean (+/- SEM) peak GH response to GHRP-2 was 20.1 +/- 5.5, 63.6 +/- 24.9 and 42.2 +/- 4.3 micrograms/l for GH-deficient, slowly growing non-GH-deficient and control children, respectively (p < 0.02 and p < 0.05 for GH-deficient vs controls and slowly growing children, respectively).
    2 context sentences
    Summary · context
    GH secretory dynamics were assessed in children with and without GH deficiency.
    Summary · context
    The GH response was measured to GH-releasing hormone (GHRH) and the GH-releasing peptide GHRP-2, administered sequentially.
  2. 02HumanNon-randomized trialActivity measurement

    In children, the peak GH response to GHRP‑2 was lower in GH-deficient children (20.1 micrograms/l) than in slowly growing non-GH-deficient children (63.6 micrograms/l).

    In plain wordsIn children, the growth hormone peak after GHRP‑2 was lower in children with growth hormone deficiency than in slowly growing children without it.

    Peptide
    GHRP-2
    Outcome
    DecreasePeak GH response to GHRP-2, GH-deficient versus slowly growing children
    Study

    n: not reported in source

    Comparator
    Slowly growing non-GH-deficient children
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Peak GH response
    20.1 micrograms/l
    GH-deficient children
    Peak GH response
    63.6 micrograms/l
    slowly growing non-GH-deficient children

    Source sentences

    Summary
    The mean (+/- SEM) peak GH response to GHRP-2 was 20.1 +/- 5.5, 63.6 +/- 24.9 and 42.2 +/- 4.3 micrograms/l for GH-deficient, slowly growing non-GH-deficient and control children, respectively (p < 0.02 and p < 0.05 for GH-deficient vs controls and slowly growing children, respectively).
    2 context sentences
    Summary · context
    GH secretory dynamics were assessed in children with and without GH deficiency.
    Summary · context
    The GH response was measured to GH-releasing hormone (GHRH) and the GH-releasing peptide GHRP-2, administered sequentially.
  3. 03HumanNon-randomized trialActivity measurement

    In children, the GH area under the curve after GHRP‑2 was 995, 2460 and 1598 micrograms/l x minute in GH-deficient, slowly growing and control children; no test result is given.

    In plain wordsIn children, the total growth hormone response to GHRP‑2 was lowest in children with growth hormone deficiency. The abstract gives no test result.

    Peptide
    GHRP-2
    Outcome
    MixedGH area under the curve after GHRP-2 by group
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    GH AUC
    995 micrograms/l x minute
    GH-deficient children
    GH AUC
    2460 micrograms/l x minute
    slowly growing non-GH-deficient children
    GH AUC
    1598 micrograms/l x minute
    control children

    Source sentences

    Summary
    Corresponding values for area under the curve (AUC) were 995 +/- 371. 2460 +/- 953 and 1598 +/- 274 micrograms/l x minute.
    2 context sentences
    Summary · context
    GH secretory dynamics were assessed in children with and without GH deficiency.
    Summary · context
    The GH response was measured to GH-releasing hormone (GHRH) and the GH-releasing peptide GHRP-2, administered sequentially.

Studies that did not test the peptide alone1

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 04HumanNot a test of GHRP-2 aloneNon-randomized trialActivity measurement

    In children, the ratio of the peak GH response to GHRP‑2 and GHRH was similar in GH-deficient, slowly growing and control children.

    In plain wordsIn children, the ratio of the growth hormone peaks after GHRP‑2 and after GHRH was similar in all three groups.

    Peptide
    GHRP-2
    Outcome
    No significant changeRatio of peak GH response to GHRP-2 and GHRH
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The ratio of the peak GH response to GHRP-2 and GHRH was similar in all three groups.
    2 context sentences
    Summary · context
    GH secretory dynamics were assessed in children with and without GH deficiency.
    Summary · context
    The GH response was measured to GH-releasing hormone (GHRH) and the GH-releasing peptide GHRP-2, administered sequentially.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.